[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345084-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345084-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","de-novo-malignancies-after-liver-transplantation-a-multicenter-cohort-study-of-incidence-timing-and-outcomes","De Novo Malignancies after Liver Transplantation - A Multicenter Cohort Study of Incidence, Timing, and Outcomes","","De novo malignancies represent a key long-term complication after liver transplantation, shaped by chronic immunosuppression and improved post-transplant survival. This multicenter cohort study analyzed clinical characteristics and temporal patterns of de novo neoplasms among adult recipients in 16 Turkish centers. Using 6943 evaluated patients, 208 with 220 histologically confirmed de novo malignancies (excluding HCC) were included, with early and timing-specific risk and outcome assessment. Results identify dominant cancer categories, strong associations with donor type, age groups, tacrolimus exposure, and a peak onset window within 2–10 years.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/de-novo-malignancies-after-liver-transplantation-a-multicenter-cohort-study-of-incidence-timing-and-outcomes/345084/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/de-novo-malignancies-after-liver-transplantation-a-multicenter-cohort-study-of-incidence-timing-and-outcomes/345084.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this multicenter cohort study?","Question",{"text":63,"@type":64},"To evaluate the clinical characteristics and temporal trends of de novo neoplasms in liver transplant recipients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many patients and malignancies were included, and what was excluded?",{"text":68,"@type":64},"From 6943 adult recipients, 208 patients with 220 histologically confirmed de novo malignancies were included; hepatocellular carcinoma was excluded.",{"name":70,"@type":61,"acceptedAnswer":71},"When do most de novo malignancies occur after liver transplantation?",{"text":72,"@type":64},"Most malignancies (76.8%) occur within 10 years post-LT, with peak incidence in the 2–10 year period.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345084,1790158661,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","ORIGINAL ARTICLE LIVER  \nDe Novo Malignancies after Liver Transplantation: A Multicenter Cohort Study of Incidence, Timing, and Outcomes*  \nNilay Danış1, Hüseyin Döngelli1, Tarkan Ünek1, Aylin Bacakoğlu1, İlker Turan2, Abdullah Zeki Karasu2, Fulya Günşar2,  \nElvan Işık2, Muhsin Murat Harputluoglu3, Kutay Sağlam3, Sezai Yılmaz3, Bilger Çavuş4, Sabahattin Kaymakoglu4, HaydarAdanır5, Dinç Dinçer5, Derya Arı6, MeralAkdogan Kayhan6 ,Dilara Turan Gokce6, Gökhan Kabacam7, Sedat Karademir7, Murat Kıyıcı8, Selcan Cesur8, Hale Gokcan9, Zeynep Melekoglu Ellik9, Ramazan İdilman9, Murat Dayangaç10, Yasemin Balaban11, Ahmet Bülent Doğrul11, Hilmi Anıl Dinçer11, GupseAdalı12, Feyza Dilber13,  \nMurat Taner Gulsen14, Orhan Sezgin15, Zekiye Nur Harput15, Murat Akyıldız16, Kenan Moral17, Tufan Egeli1, CihanAğalar1, Mücahit Özbilgin1, MesutAkarsu1  \n1Liver Transplantation Center, Dokuz Eylül University Hospital, İzmir, Türkiye  \n2Liver Transplantation Center, Ege University Hospital, İzmir, Türkiye  \n3Liver Transplantation Center, İnonu University Hospital, Malatya, Türkiye  \n4Liver Transplantation Center, İstanbul University Hospital, İstanbul, Türkiye  \n5Liver Transplantation Center, Akdeniz University Hospital, Antalya, Türkiye  \n6Liver Transplantation Center, Ankara Bilkent City Hospital, Ankara, Türkiye 7Liver Transplantation Center, Güven Hospital, Ankara, Türkiye  \n8Liver Transplantation Center, Bursa Uludağ University Hospital, Bursa, Türkiye  \n9Liver Transplantation Center, Ankara University Hospital, Ankara, Türkiye  \n10Liver Transplantation Center, İstanbul Medipol University Hospital, İstanbul, Türkiye 11Liver Transplantation Center, Hacettepe University Hospital, Ankara, Türkiye  \n12Liver Transplantation Center, Ümraniye Training and Research Hospital, İstanbul, Türkiye  \n13Liver Transplantation Center, Marmara University Hospital, İstanbul, Türkiye  \n14Liver Transplantation Center, Gaziantep University Hospital, Gaziantep, Türkiye  \n15Liver Transplantation Center, Mersin University Hospital, Mersin, Türkiye  \n16Liver Transplantation Center, Koç University Hospital, İstanbul, Türkiye 17Liver Transplantation Center, Ankara Gazi University Hospital, Ankara, Türkiye  \nCite this article as: Danış N, Döngelli H, Ünek T, et al. De novo malignancies after liver transplantation: A multicenter cohort study of incidence, timing, and outcomes. Turk J Gastroenterol. 2026;37(4):510-523 .  \nABSTRACT  \nBackground/Aims: De novo malignancies are an important long-term complication following liver transplantation (LT), driven by chronic immunosuppression and extended post-transplant survival. Understanding patterns by tumor type, timing, and patient characteristics is essential for optimized surveillance. This study aimed to evaluate the clinical characteristics and temporal trends of de novo neoplasms in LT recipients.  \nMaterials and Methods: A total of 6943 adult LT recipients from 16 Turkish centers were evaluated between 1999 and 2023). Two hundred eight patients with 220 histologically confirmed de novo malignancies (excluding hepatocellular carcinoma) were included. Patients who died within 30 days or developed cancer within 90 days post-LT were excluded. Incidence and mortality rates were assessed across post-transplant intervals.  \nResults: Non-skin solid (53.2%), dermatologic (28.6%), and hematologic (18.2%) cancers were predominant. Most malignancies (76.8%) occurred within 10 years post-LT. Early-onset (\u003C10 years) malignancies were more common in living donor recipients (62. 7%, P = . 001) and associated with higher mortality (39. 6% vs. 11.8%, P \u003C . 001). Recipients ≤60 years exhibited a higher incidence of hematologic cancers (23. 9% vs. 12. 6%, P = . 03) and increased mortality (39.4% vs. 27. 0%, P = . 05). In subgroup analysis, tacrolimus use was strongly associated with cutaneous squamous cell carcinoma (P = .004). Peak incidence occurred 2-10 years post-LT (≈ 13-14 per 1000 recipients), with non-skin solid tumors being the most frequ","cbCaingj7oxssmQZ","https://ap.wps.com/l/cbCaingj7oxssmQZ","pdf",2056941,14,"English","# Abstract\n## Background/Aims\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n## Clinical context and long-term risks","[{\"question\":\"What is the main purpose of this multicenter cohort study?\",\"answer\":\"To evaluate the clinical characteristics and temporal trends of de novo neoplasms in liver transplant recipients.\"},{\"question\":\"How many patients and malignancies were included, and what was excluded?\",\"answer\":\"From 6943 adult recipients, 208 patients with 220 histologically confirmed de novo malignancies were included; hepatocellular carcinoma was excluded.\"},{\"question\":\"When do most de novo malignancies occur after liver transplantation?\",\"answer\":\"Most malignancies (76.8%) occur within 10 years post-LT, with peak incidence in the 2–10 year period.\"}]","De Novo Malignancies after Liver Transplantation - A Multicenter Cohort Study of Incidence, Timing, and Outcomes | PDF",1790056466,35,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b212b8eacb929d04f5ab76e55dc00e61.webp",983,1280,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e60c8bfbd34a439daed5d8e26e5d7db.webp",982,1278,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/370b126a16e47ecd7df9beb77eff5440.webp",981,1277,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3124ac36e0a1044c906267ef87ef8f68.webp",980,1276]